Clinical Trials Browser

Phase 1/2 × Recurrence × 30 days × Clear all

NCT06634589 2026-03-18

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT07416188 2026-03-18

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Phase 1/2 Not yet recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT07480213 2026-03-18

DART-NK-SCLC

Phase 1/2 Recruiting

Recurrence, Small Cell Lung Carcinoma

NCT07480954 2026-03-18

DUAL-OV-CAR-NK

Phase 1/2 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT06161519 2026-03-17

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Phase 1/2 Recruiting

Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Recurrence

NCT04347616 2026-03-16

NK4AML

Phase 1/2 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05588141 2026-03-13

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Phase 1/2 Recruiting

Brain Neoplasms, Glioma, Neoplasms, Recurrence

NCT06639607 2026-03-10

PRiME II

Phase 1/2 Not yet recruiting

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05533775 2026-03-06

iMATRIX GLO

Phase 1/2 Recruiting

Recurrence

NCT04416984 2026-03-04

ALPHA2

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05826535 2026-02-24

Study of LYL314 in Aggressive Large B-Cell Lymphoma

Phase 1/2 Recruiting

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT07116616 2026-02-24

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT07123454 2026-02-24

Lumi-NHL

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT02942264 2026-02-23

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Phase 1/2 Terminated

53 enrolled 22 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Recurrence, Gliosarcoma

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

Neoplasms, Recurrence

NCT06051695 2026-02-20

EVEREST-2

Phase 1/2 Recruiting

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence

NCT03686124 2026-02-18

ACTengine

Phase 1/2 Recruiting

DermatologicGynecologic

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence